Search Results - "Hoogi, Shiran"
-
1
A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function
Published in Journal for immunotherapy of cancer (09-09-2019)“…BackgroundTumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint…”
Get full text
Journal Article -
2
Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor
Published in Frontiers in immunology (29-09-2017)“…Recent developments in cancer treatment are demonstrating the increasing and powerful potential of immunotherapeutic strategies. In this regard, the adoptive…”
Get full text
Journal Article -
3
Genetically engineering glycolysis in T cells increases their antitumor function
Published in Journal for immunotherapy of cancer (04-07-2024)“…BackgroundT cells play a central role in the antitumor response. However, they often face numerous hurdles in the tumor microenvironment, including the…”
Get full text
Journal Article -
4
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
Published in Advanced drug delivery reviews (15-02-2019)“…The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically…”
Get full text
Journal Article -
5
Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells
Published in Cancer immunology research (01-10-2024)“…Cancer exploits different mechanisms to escape T-cell immunosurveillance, including overexpression of checkpoint ligands, secretion of immunosuppressive…”
Get more information
Journal Article